Bionest

“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies

The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...

Bionest

Personalized Cancer Therapies: Time to Take Lessons from “Orphan Drugs”

We recently wrote about rare disease drug development and commercialization, and why such franchises succeed better within small companies or perhaps as stand-alone, independently operating units of larger firms. When the patient population targeted by a particular therapy is small, success depends on a highly patient-centric approach to both drug development and commercialization. One must...

Bionest

Orphan Drug Franchises Best Left to Mature Alone

Commercial success in the rare disease field depends on a highly patient-centric approach that connects effectively with rare disease patient communities at a senior management level and focuses on access and interactions with thought leaders and physicians, rather than on selling drug features and benefits. This is the topic of our latest contributed article for...

Bionest

Visit Us at the JP Morgan Healthcare Conference – Jan 11-14 in San Francisco!

We are looking forward to attending the JP Morgan Healthcare Conference again January 11-14, 2016, in San Francisco.   Three of Bionest’s leaders, Alain J. Gilbert, Olivier Lesueur, and Bob Easton, will be available to meet one-on-one for 30 minutes in our private suite, between Monday Jan 11 and Thursday Jan 14.   For Bionest,...